FDA’s Center for Biologics Research and Review (CBER) issued its FY2016 annual summary of biological product and HCT/P deviation reports. Included in the analysis are reports submitted by: • manufacturers of licensed biological products other than blood and blood components • licensed manufacturers of blood and blood components, including source plasma • unlicensed registered blood establishments, and • transfusion services.
[/membership][membership level=”0,4″][The content continues for paid members only.]
Login or Subscribe [/membership][membership level=”1,5,6,7,8,9,10,11,12″][membership]
